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ABSTRACT
Background and Objectives: Long-term administration
of tamoxifen causes endometrial changes. The aim of this
study was to evaluate the role of transvaginal sonogra-
phy and vaginoscopic hysteroscopy in the screening of
patients on tamoxifen. 
Methods: Seventy patients with breast cancer treated
with tamoxifen 20 mg daily underwent transvaginal
sonography and vaginoscopic hysteroscopy, a modified
relatively painless approach, at the beginning of the
treatment and at a follow-up visit approximately 9
months after its initiation.
Results: At the follow-up visit, the mean uterine dimen-
sions and mean endometrial thickness as measured by
ultrasound were significantly larger, and pulsatility and
resistance indices of the uterine arteries as measured by
Doppler were significantly lower. Sonography revealed
abnormal endometrial thickness in 73% (51 of 70) of the
patients, and 83% (58 of 70) had hysteroscopical
changes. Sonography missed 1 case of endometrial ade-
nocarcinoma.
Conclusions: Vaginoscopic hysteroscopy, an approach
that causes reduced pain, can add significantly to the
sensitivity of transvaginal sonography for the detection of
endometrial changes in patients with breast cancer
receiving tamoxifen. It is recommended for every patient
prior to the initiation of treatment and at the follow-up
visits.
Key Words: Tamoxifen, Vaginoscopic hysteroscopy,
Transvaginal sonography, Endometrium.
INTRODUCTION
Tamoxifen is a nonsteroid antiestrogen, which has been
principally used successfully in the adjuvant treatment
and chemoprevention of disseminated receptor-positive
breast cancer, particularly in postmenopausal women. It
has been established that the long-term administration of
tamoxifen causes several changes in the endocervix and
endometrium (atrophy, polyposis, proliferation, vascular
changes),1 and indications exist that women on tamox-
ifen may be at increased risk of developing endometrial
carcinoma.2 It is, therefore, reasonable that such women,
even if they are asymptomatic, must be under careful
surveillance. 
Transvaginal ultrasonography, sonohysterography, and
hysteroscopy have been used in the examination of such
women. However, controversy exists regarding the most
optimal method of screening, but in most of the com-
parative studies the method that was used was conven-
tional hysteroscopy. In this study, we used vaginoscopic
hysteroscopy,3 a relatively new and painless approach,
transvaginal ultrasonography, and cytopathology for the
investigation of tamoxifen-induced endometrial changes,
and compared their performance.
MATERIALS AND METHODS
The study population consisted of 70 patients (mean age:
57.6 years ± 7.1 SD, range: 42 to 71) who had undergone
modified radical mastectomy for breast cancer in our
department and were receiving 20 mg of tamoxifen daily
orally.
Every woman underwent transvaginal sonography (TVS)
and vaginoscopic hysteroscopy before the initiation of
tamoxifen treatment. TVS was used for the measurement
of uterine dimensions and endometrial thickness, and
Doppler analysis was used for the calculation of pulsatil-
ity and resistance indices (PI and RI, respectively) of both
uterine arteries. Endometrial thickness over 4 mm for
postmenopausal and over 6 mm for premenopausal
women was considered abnormal. We used a 5-MHz
Toshiba transducer. Vaginoscopic hysteroscopy was per-
formed using the rigid Hamou contact Microhystero-
scope I of 5-mm diameter or the Bettocchi 3.5-mm hys-
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teroscope (Karl Storz, Tuttligen, Germany), at 1 x magni-
fication for panoramic examination and at 20 x for micro-
hysteroscopy. The vagina and the uterus were dilated
with carbon dioxide. The procedure has been previously
described in detail.4 Vaginoscopic hysteroscopy was well
tolerated by approximately 96% (67 of 70) of our patients,
and no anesthesia (general or local) was used. Every
woman was reevaluated with TVS and vaginoscopic hys-
teroscopy after a mean interval of 8.7 months (range: 5.2
to 13.4 months). At reevaluation, 62 women (88.6%) were
asymptomatic, and 8 (11.4%) presented with abnormal
uterine bleeding.
When hysteroscopy was suggestive of stromal prolifera-
tion, hysteroscopically directed biopsies were taken.
When endometrial hypervascularity was found on hys-
teroscopy, the woman was followed up without biopsies.
Endometrial polyps were resected if possible. In selected
cases, where a high suspicion existed of malignancy
based on the sonographic and hysteroscopic findings,
dilatation and curettage (D&C) or endometrial resection
and pathological examination were performed.
RESULTS
In most of the patients (64 of 70, 94%), the endometrial
thickness in the initial sonographic examination was
within normal limits. Six patients (6%) had endometrial
thickening, and underwent D&C. The histopathological
examination revealed focal or complex hyperplasia with-
out atypia. The initial hysteroscopic findings were in
accordance with the sonographic ones.
The follow-up sonographic examination, approximately 9
months after the initiation of tamoxifen administration,
revealed abnormal endometrial thickness in 51 women (73%). 
In the entire study population (70 women), the follow-up
TVS measurements were significantly different from the
initial ones (Table 1). Specifically, the long axis of the
uterus had a mean length of 52 mm as opposed to the
previous TVS in which it was 42 mm. The mean maxi-
mum transverse diameter was 41 mm, but in the previous
TVS it was 33 mm (P < 0.001). The endometrial thickness
reached 7.9 ± 3.6 mm compared with 4.5 ± 1.8 mm in the
initial TVS examination (P < 0.001). The mean PI and RI
of the uterine arteries were 2.1 ± 0.5 and 0.83 ± 0.07,
respectively, and they were significantly lower than those
calculated before the initiation of tamoxifen administra-
tion 2.7 ± 0.16 and 0.88 ± 0.02, respectively (P < 0.001).
The hysteroscopic examination performed after the TVS
revealed changes in 58 (83%) women. Specifically, we
noted:
1. Smooth, white epithelium of the vagina, endocervix, 
and endometrium (stromal proliferation) in 24 
women [34.3%, 23 to 45.6% (95% CI)];
2. Presence of endocervical or endometrial polyp-like
protuberances surrounded by hypervascularized 
endometrium in 13 women [18.6%, 9.3 to 27.9% 
(95% CI)];
3. Atypical endometrial hypervascularity as a simple 
finding in 19 women [27.1%, 16.5 to 37.7% (95% CI)];
4. Hysteroscopic image resembling adenocarcinoma of 
the endometrium, which was confirmed pathologi-
cally after a D&C in 2 women [2.8%, 0.1 to 6.7% 
(95% CI)]. 
Histopathological examination was in agreement with
hysteroscopical findings in the 24 women where hys-
teroscopy was suggestive of stromal proliferation and in
both cases where hysteroscopy was suggestive of ade-
nocarcinoma. TVS missed 1 of 2 cases of histopathologi-
cally confirmed adenocarcinoma. In 9 of the 13 women
with a hysteroscopical finding of endometrial polyp, the
polyps could be resected and histopathological examina-
tion revealed tamoxifen polyps.
DISCUSSION
Although classically described as an estrogen antagonist,
tamoxifen can activate certain estrogenic effects, and no
Table 1.
Ultrasonographic measurements (mean ± standard deviation) in
the pretreatment and in the follow-up examination.
Measurements Pretreatment Follow-up P value*
Long axis of the uterus 42 ± 5 mm 52 ± 7 mm <.001
Maximum transverse 
diameter 33 ± 4 mm 41 ± 5 mm <.001
Endometrial thickness 4.5 ± 1.8 mm 7.9 ± 3.6 mm<.001
Pulsatility index 2.7 ± 0.16 2.1 ± 0.5 <.001
Resistance index 0.88 ± 0.02 0.83 ± 0.07 <.001
* P value estimated with the Student’s t-test.doubt in some circumstances this drug can act as an
estrogen agonist causing stromal proliferation, endocer-
vical, or endometrial polyp-like protuberances and
endometrial hypervascularity.1 This is also confirmed by
our study. 
It has been established that women on tamoxifen should
be evaluated for endometrial changes. The value of TVS
in the follow-up of such women has been well-docu-
mented,5 and in 1 study it was even found to be superi-
or to office hysteroscopy.6 However, evidence suggests
that TVS has a high number of false-positive findings.7 In
this study, we noted abnormal sonographic findings in
73% of the patients on tamoxifen and abnormal hystero-
scopic findings in 83%. With TVS, those lesions appeared
as an abnormal endometrial thickness, but with
vaginoscopic hysteroscopy they were more specified
(polyps, protuberances, hypervascularity, and other such
things). One of the main points against hysteroscopy as
a screening test in women receiving tamoxifen is its lim-
ited acceptability from the patient. Considering that
vaginoscopic hysteroscopy, the modified approach we
used in this study, is an atraumatic and acceptable
method for the patients,4,8 we believe that it has an
advantage over TVS for the diagnostic approach of
endometrial changes caused by tamoxifen. In
vaginoscopic hysteroscopy, a speculum is not used and
the cervix is not clamped, thereby reducing patient dis-
comfort. General or even local anesthesia is not required.
With this method, one also has the ability to visualize the
vaginal epithelium.
A recent study suggested that a high-risk group of
patients could be identified at the evaluation prior to the
initiation of tamoxifen treatment.9 The fact that in our
study patients with abnormal pretreatment findings
underwent D&C does not allow us to test this conclu-
sion. 
No consensus exists regarding the most appropriate
method of surveillance of tamoxifen-treated women. In
recent studies, endometrial assessment by TVS is recom-
mended reserving hysteroscopy for women with a thick
endometrium.5,10 Sonohysterography is another method
that has been proposed for the evaluation of such
patients.11 Based on the results of our study, we propose
sonographic evaluation and vaginoscopic hysteroscopy
prior to tamoxifen treatment. In the follow-up visits,
these women should undergo TVS, vaginoscopic hys-
teroscopy, and cytological examination (endometrial
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brushing-cell block) of the collected sample. Finally, we
recommend D&C mostly in symptomatic women with
abnormal uterine bleeding.
CONCLUSION
Vaginoscopic hysteroscopy is a modified approach that
causes reduced pain and is well tolerated by almost
every patient. In addition, the screening of patients with
breast cancer receiving tamoxifen can increase signifi-
cantly the sensitivity and specificity of transvaginal
sonography in the detection of endometrial changes. It is
recommended in every patient prior to the initiation of
treatment and at the follow-up visits.
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